Tolerability of anastrozole (A) compared with tamoxifen (T): Mature data in the adjuvant setting - Data reported on behalf of the ATAC ('arimidex', tamoxifen, alone or in combination) trialists' group

被引：0

作者：

Mansel, Robert ^{[1
]}

机构：

[1] Univ Wales Hosp, Dept Surg, Cardiff, Wales

来源：

ANNALS OF ONCOLOGY | 2006年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：94 / 94

页数：1

共 50 条

[41] Data from the arimidex, tamoxifen, alone or in combination (ATAQ trial: Implications for use of aromatase inhibitors in 2003
Buzdar, AU
CLINICAL CANCER RESEARCH, 2004, 10 (01) : 355S - 361S
[42] The arimidex, alone or in combination (ATAC) adjuvant breast cancer trial: Baseline endometrial sub-protocol data
Duffy, S
Jackson, TL
EUROPEAN JOURNAL OF CANCER, 2002, 38 : S83 - S83
[43] Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer
David Cella
Lesley Fallowfield
Peter Barker
Jack Cuzick
Gershon Locker
Anthony Howell
Breast Cancer Research and Treatment, 2006, 100 : 273 - 284
[44] Fewer gynaecological adverse events (AEs), gynaecological interventions, endometrial changes and abnormalities with anastrozole than with tamoxifen: findings from the ATAC ('Arimidex', Tarmoxifen, Alone or in Combination) trial
Distler, W.
BREAST, 2007, 16 : S45 - S46
[45] Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer
Cella, David
Fallowfield, Lesley
Barker, Peter
Cuzick, Jack
Locker, Gershon
Howell, Anthony
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 (03) : 273 - 284
[46] Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the Arimidex (A), Tamoxifen (T), Alone or in Combination (ATAC) Trial.
Cella, D
Fallowfield, L
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 23S - 23S
[47] The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment
Duffy, S
Jackson, TL
Lansdown, M
Philips, K
Wells, M
Pollard, S
Clack, G
Coibion, M
Bianco, AR
HUMAN REPRODUCTION, 2006, 21 (02) : 545 - 553
[48] Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: A US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial
Locker, Gershon Y.
Mansel, Robert
Cella, David
Dobrez, Deborah
Sorensen, Sonja
Gandhi, Sanjay K.
BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 (02) : 229 - 238
[49] Aromatase inhibitors in prevention - Data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second international breast cancer intervention study)
Cuzick, J
TUMOR PREVENTION AND GENETICS, 2003, 163 : 96 - 103
[50] Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial
Gershon Y. Locker
Robert Mansel
David Cella
Deborah Dobrez
Sonja Sorensen
Sanjay K. Gandhi
Breast Cancer Research and Treatment, 2007, 106 : 229 - 238

← 1 2 3 4 5 →